TrialJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2014

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.

M W Konstan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.